Akura Medical
                                                                                                                                    
                                                                                                United States
                                                 -                                                 Los Gatos, California
                                                                                            
                                                                                    - 04/10/2023
 - Series B
 - $35,000,000
 
Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms (VTE)
- Industry Medical Device
 - Website https://www.akuramed.com/
 - LinkedIn https://www.linkedin.com/company/akura-med/about/
 
Related People
Murali SrivathsaFounder
                                                    
                                                                                                                United States -
                                                         San Francisco Bay Area
                                                    
                                                Mission-driven, versatile Medical Devices leader who can introduce bold solutions and strategic plans which drive rapid business and operational growth, translate cutting-edge concepts into game-changing commercial offerings, and seize emerging opportunities through a balanced mix of strategic partnerships, financial planning, and business due diligence. The answer to my "Why?" is to make a transformative change in the lives of patients and those who treat them. 
✓ Consistently delivers high growth/profitability through vital blend of product innovation and commercialization, go-to-market strategies, transformational approaches to Education & Training, and operational plans. Proven business and leadership record honed across multiple functions from management to strategy, M&A, to R&D.
✓ Credited with leading matrix organizations in the development of next-gen product lines at Abbott and Guidant (Boston Scientific CRM), accounting for $900+Mn in annual revenues. 
✓ Expert relationship management skills and emotional intelligence to build high-performance internal cross-functional teams, as well as long-lasting external strategic partnerships.
✓ Experience with building funding strategies and leading fundraises. 
✓ Enjoys the challenges of new initiatives- excels at being able to add value with a singular combination of scientific and business acumen.
✓ Broad experience in both domestic and international markets. 
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                Zeeg |  $1,265,935  | (Nov 4, 2025)
                            
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                            
                                                
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                
                                                
                                                
                                                
                                                
                                                
                                                    
                                                
                                                    
                                                
                                                
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)
                                                                        
                                octonomy |  $20,000,000  | (Nov 4, 2025)
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                Indomo |  $25,000,000  | (Nov 4, 2025)
                                                                        
                                AUI™ (Augmented Intelligence) |  $20,000,000  | (Nov 4, 2025)
                                                                        
                                Popai Health |  $11,000,000  | (Nov 4, 2025)
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025)